X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.forbes.com/sites/johnlamattina/2019/04/10/the-biopharmaceutical-cartel-and-high-drug-prices/#4fb4c4e6533c
https://www.reuters.com/article/us-column-miller-medicare/medicare-part-d-no-match-for-runaway-specialty-drug-costs-study-idUSKCN1PW16X
https://www.fiercepharma.com/manufacturing/merck-runs-out-parkinson-s-disease-drug-sinemet-as-manufacturing-issues-unexpected
http://thehill.com/policy/healthcare/397970-merck-to-lower-prices-for-some-drugs
http://thepeninsulaqatar.com/article/25/02/2017/Merck-write-downs-$1.9bn-as-market-shrinks
http://www.businesstimes.com.sg/consumer/merck-takes-us19b-writedown-as-hepatitis-c-market-shrinks
http://www.fiercepharma.com/pharma/merck-falls-short-q4-sales-but-sees-eps-growth-ahead
http://www.pmlive.com/pharma_news/two_new_hepatitis_c_therapies_fast-tracked_in_europe_1184949
http://www.pharmatimes.com/news/smc_oks_four_new_therapies_for_nhs_use_in_scotland_1184395
http://www.fiercepharma.com/marketing/abbvie-s-pan-genotypic-hep-c-prospect-shines-trials-putting-heat-rival-gilead
http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx
http://www.pharmatimes.com/news/nice_nods_for_tagrisso,_cimzia_and_zepatier_1174814
http://www.biospace.com/News/study-stopped-early-as-merck-co-s-immunotherapy/436420/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.pharmatimes.com/news/nice_green_light_for_mercks_hepatitis_c_drug_zepatier_1126547
https://www.pharmacompass.com/pdf/news/merck-sharp-dohme-limiteds-zepatier-grazoprevir-elbasvir-receive-market-authorisation-in-eu-for-hepatitis-c-chronic-1464602177.pdf
http://www.raps.org/Regulatory-Focus/News/2016/05/03/24862/FDA-Calls-for-Head-to-Head-Trials-in-Revised-Draft-Guidance-on-Hepatitis-C-Drugs/
http://www.pharmafile.com/news/503902/merck-says-its-zepatier-showed-better-efficacy-and-safety-compared-competition-phase-iii
http://www.bloomberg.com/news/articles/2016-02-23/drug-spending-slowed-in-2015-after-discounts-cvs-health-says
http://www.fiercepharma.com/story/gilead-nabs-two-new-harvoni-approvals-hep-c-contest-heats/2016-02-17
http://www.prnewswire.com/news-releases/diplomat-to-dispense-zepatier-to-treat-patients-with-chronic-hepatitis-c-virus-300220853.html
http://www.fiercebiotech.com/story/top-10-possible-blockbusters-might-launch-year/2016-01-28
http://www.pmlive.com/pharma_news/merck_and_co_posts_positive_hepatitis_c_data_868992?
http://www.pharmatimes.com/Article/15-10-06/Merck_drug_could_offer_Hep_C_cure_to_kidney_disease_patients.aspx
http://www.bloomberg.com/news/articles/2015-07-28/merck-targets-toughest-cases-for-foothold-in-hepatitis-c-market
http://www.fiercepharma.com/story/hep-c-landscape-shifts-again-bms-combo-nabs-breakthrough-tag/2015-05-20
http://www.biospectrumasia.com/biospectrum/regulatory/220928/fda-stamps-mercks-hep-c-drug-breakthough-therapy
http://www.biospace.com/News/will-abbvies-hcv-candidates-threaten-gilead/371707/source=TopBreaking
Market Place
Share 
